Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis

Quantum Biopharma Ltd. (QNTM) — Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapyTORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company focused on developing innovative therapies and technologies, today announced that it has entered into a Study Start-Up Agreement (“SUA”) with the clinical research business of T

Source: GlobeNewswire — read the full announcement there.

Browse more sector announcements in our press release archive.